BioPharm International serves as the voice of an experienced mentor to the biopharmaceutical community.

BioPharm International provides a forum for its readers to exchange practical, hands-on information for developing and manufacturing pharmaceutical products through biotechnology; and serves as a supportive, authoritative voice in the evolving business, regulatory, scientific, and technical areas of the biopharmaceutical industry.

BioPharm International is the longest running peer-reviewed publication serving professionals involved in developing and manufacturing biotech therapeutics.

This global audience comprises of scientists, directors and executives in R&D, quality assurance/validation, process development, manufacturing, regulatory affairs and other professionals involved in critical functional units of biopharmaceutical organizations.

Qualify for Your Free Subscription to BioPharm International

Geographic Eligibility: USA & Europe

Offered Free by: Advanstar Communications, Inc.

BIOPHARM INTERNATIONAL serves the field of biopharmaceutical technology including biopharmaceutical manufacturing, biologics manufacturing, classical pharmaceutical manufacturing, biodiagnostic manufacturing, biopharmaceutical and biologics process development, biodiagnostic process development, biotherapeutic discovery and development, biopharmaceutical formulation and delivery, transgenic therapeutic productions, biotechnology research and biopharmaceutical research.

BIOPHARM INTERNATIONAL also serves specialty or bulk chemical manufacturing, architecture, engineering, construction, contract research and analytical services, government; universities, colleges, and research institutes; business, investment, and legal services; and others allied to the field.

Visit BioPharm International Website

NEWS
Vetter Installs Six Automatic Packaging Lines at its New Facility
Vetter Pharma International (Ravensburg, Germany) has completed the installation of six automatic packaging lines at Vetter Secondary Packaging (VSP), the company?s new packaging services facility.

Three Shared Audit Models Tested at Rx-360 Consortium's Launch Meeting
The newly formed Rx-360 consortium had an impressive turnout of over 125 people at its launch meeting in Washington, DC, on June 5.

Genzyme Detects Virus Contamination of Bioreactor, Halts Production
Genzyme Corporation has halted production at its manufacturing plant in Allston Landing, MA, because it has detected a virus that impairs cell growth in one of the six bioreactors there.

14 Years of Market Exclusivity Unnecessary, says FTC
A new report by FTC, entitled ?Follow-on Biologic Drug Competition,? examines whether the price of biologics is likely to be reduced by competition from FOBs.

Comments (0)

Name

Email

Comment

smaller | bigger

Add Comment